الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
Identification and estimation of a collagenase enzyme in patients with colon cancer: Colorectal cancer (CRC) is treatable disease if diagnosed early. However, current screening methods are suboptimal and no serum-based test is sufficient for widespread use. Here we evaluated the efficacy of metalloprotenase-1 (MMP-1) as a non-invasive marker for early CRC diagnosis. Our study exhibited that MMP-1 alone or combined with other markers can be a promising biomarker for CRC diagnosis. This study included colon cancer patients (n=120), benign growth patients (n=75) and normal individuals (n=56). MMP-1 was recognized using western blotting and quantified by ELISA then receiver-operating characteristic curve (ROC) was used for measuring its diagnostic performance. In colon cancer patients, MMP-1 was identified at 245 KDa and the mean level of MMP-1 in colon cancer patients )0.3±3.0( lower than patients with benign growth (4.6 ± 0.9) and healthy individuals (5.7±0.8) with high significant difference (P < 0.0001). Additionally, the mean levels of MMP-1 were significantly (P < 0.05) decreased with late stages, lymph node invasion, distant organ metastasis and high grades. Based on ROC analysis, MMP-1 yielded a good diagnostic performance for colon cancer detection, where it had an area under the curve (AUC) 0.84 (sensitivity75.0%, specificity 82.5%) to distinguish between colon cancer patients and all non-cancerous. Also, MMP-1 had an area under the curve (AUC)= 0.79 (sensitivity70.0%, specificity 75.0) to distinguish between colon cancer patients and benign disorders. Multivariate analysis yielded colon-score that had a valuable diagnostic power in colon cancer early diagnosis as it had AUC 0.77 in distinguishing between patients with benign growth and those with early stages (sensitivity 68.0%, specificity 73.0%). In conclusion, MMP-1 can be used as an effective biomarker for colon cancer diagnosis particularly for differentiates early tumor stages from benign disorders.